TI
CERO

Telemetry Investments’s CERo Therapeutics CERO Stock Holding History

Telemetry Investments’s Portfolio CERO Stock Details CERO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-15
Closed -$304K – 192
2021
Q4 		$304K Buy
+15
New +$298K 0.39% 89

Other funds holding CERO

BCM
Beryl Capital Management Redondo Beach, California $110M AUM 317.92% 1-Year Est. Return
HCM
Highbridge Capital Management New York $3.09B AUM 31.21% 1-Year Est. Return
CF
Cantor Fitzgerald New York $6.78B AUM 28.97% 1-Year Est. Return
MI
MMCAP International Grand Cayman, Cayman Islands $1.16B AUM 76.63% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
SCM
Saba Capital Management New York $3.62B AUM 12.96% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
PAMP
Polar Asset Management Partners Toronto, Ontario, Canada $5.01B AUM 35.02% 1-Year Est. Return
PC
Periscope Capital Toronto, Ontario, Canada $902M AUM 6.27% 1-Year Est. Return

Telemetry Investments's CERO Position: Q1 2022 in Review

Telemetry Investments sold out of CERo Therapeutics (CERO) in Q1 2022, closing a stake of 15 shares — an estimated $304K sold.

Telemetry Investments first reported a position in CERO in Q4 2021 and held it in 1 quarter. The position peaked at $304K in Q4 2021. 45 funds tracked by Wall St. Rank hold CERO as of Q1 2022.

  • Telemetry Investments reported no remaining CERo Therapeutics position as of Q1 2022 after selling out during the quarter.
  • Telemetry Investments sold 15 CERo Therapeutics shares in Q1 2022, an estimated $304K.
  • Telemetry Investments first reported a position in CERo Therapeutics in Q4 2021 and held it in 1 quarter.
  • Telemetry Investments's CERo Therapeutics position peaked at $304K in Q4 2021.
  • 45 funds tracked by Wall St. Rank held CERo Therapeutics as of Q1 2022.

Based on Telemetry Investments's 13F filing for Q1 2022, filed 16 May 2022.